485 related articles for article (PubMed ID: 29391527)
21. Heterozygous Mutations in SMARCA2 Reprogram the Enhancer Landscape by Global Retargeting of SMARCA4.
Gao F; Elliott NJ; Ho J; Sharp A; Shokhirev MN; Hargreaves DC
Mol Cell; 2019 Sep; 75(5):891-904.e7. PubMed ID: 31375262
[TBL] [Abstract][Full Text] [Related]
22. SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines.
Ehrenhöfer-Wölfer K; Puchner T; Schwarz C; Rippka J; Blaha-Ostermann S; Strobl U; Hörmann A; Bader G; Kornigg S; Zahn S; Sommergruber W; Schweifer N; Zichner T; Schlattl A; Neumüller RA; Shi J; Vakoc CR; Kögl M; Petronczki M; Kraut N; Pearson MA; Wöhrle S
Sci Rep; 2019 Aug; 9(1):11661. PubMed ID: 31406271
[TBL] [Abstract][Full Text] [Related]
23. The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes.
Huang SC; Ng KF; Chang IY; Chang CJ; Chao YC; Chang SC; Chen MC; Yeh TS; Chen TC
PLoS One; 2021; 16(1):e0245356. PubMed ID: 33481850
[TBL] [Abstract][Full Text] [Related]
24. Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma.
Endo M; Yasui K; Zen Y; Gen Y; Zen K; Tsuji K; Dohi O; Mitsuyoshi H; Tanaka S; Taniwaki M; Nakanuma Y; Arii S; Yoshikawa T
Liver Int; 2013 Jan; 33(1):105-17. PubMed ID: 23088494
[TBL] [Abstract][Full Text] [Related]
25. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
[TBL] [Abstract][Full Text] [Related]
26. Ovarian high-grade serous carcinoma cells with low SMARCA4 expression and high SMARCA2 expression contribute to platinum resistance.
Kido K; Nojima S; Motooka D; Nomura Y; Kohara M; Sato K; Ohshima K; Tahara S; Kurashige M; Umeda D; Takashima T; Kiyokawa H; Ukon K; Matsui T; Okuzaki D; Morii E
J Pathol; 2023 May; 260(1):56-70. PubMed ID: 36763038
[TBL] [Abstract][Full Text] [Related]
27. Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancers.
Rago F; DiMare MT; Elliott G; Ruddy DA; Sovath S; Kerr G; Bhang HC; Jagani Z
Biochem Biophys Res Commun; 2019 Jan; 508(1):109-116. PubMed ID: 30527810
[TBL] [Abstract][Full Text] [Related]
28. Expression of SMARCA2 and SMARCA4 in gastric adenocarcinoma and construction of a nomogram prognostic model.
Zhang Z; Li Q; Sun S; Li Z; Cui Z; Liu Q; Zhang Y; Xiong S; Zhang S
Int J Clin Oncol; 2023 Nov; 28(11):1487-1500. PubMed ID: 37634210
[TBL] [Abstract][Full Text] [Related]
29. A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers.
Peng L; Li J; Wu J; Xu B; Wang Z; Giamas G; Stebbing J; Yu Z
Front Immunol; 2021; 12():762598. PubMed ID: 34675941
[TBL] [Abstract][Full Text] [Related]
30. Switch/sucrose nonfermenting nucleosome complex-deficient colorectal carcinomas have distinct clinicopathologic features.
Villatoro TM; Ma C; Pai RK
Hum Pathol; 2020 May; 99():53-61. PubMed ID: 32222462
[TBL] [Abstract][Full Text] [Related]
31. SWI/SNF complexes are required for full activation of the DNA-damage response.
Smith-Roe SL; Nakamura J; Holley D; Chastain PD; Rosson GB; Simpson DA; Ridpath JR; Kaufman DG; Kaufmann WK; Bultman SJ
Oncotarget; 2015 Jan; 6(2):732-45. PubMed ID: 25544751
[TBL] [Abstract][Full Text] [Related]
32. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
Vangamudi B; Paul TA; Shah PK; Kost-Alimova M; Nottebaum L; Shi X; Zhan Y; Leo E; Mahadeshwar HS; Protopopov A; Futreal A; Tieu TN; Peoples M; Heffernan TP; Marszalek JR; Toniatti C; Petrocchi A; Verhelle D; Owen DR; Draetta G; Jones P; Palmer WS; Sharma S; Andersen JN
Cancer Res; 2015 Sep; 75(18):3865-3878. PubMed ID: 26139243
[TBL] [Abstract][Full Text] [Related]
33. SWI/SNF-deficient thoraco-pulmonary neoplasms.
Sesboue C; Le Loarer F
Semin Diagn Pathol; 2021 May; 38(3):183-194. PubMed ID: 33451916
[TBL] [Abstract][Full Text] [Related]
34. Rhabdoid and Undifferentiated Phenotype in Renal Cell Carcinoma: Analysis of 32 Cases Indicating a Distinctive Common Pathway of Dedifferentiation Frequently Associated With SWI/SNF Complex Deficiency.
Agaimy A; Cheng L; Egevad L; Feyerabend B; Hes O; Keck B; Pizzolitto S; Sioletic S; Wullich B; Hartmann A
Am J Surg Pathol; 2017 Feb; 41(2):253-262. PubMed ID: 27984237
[TBL] [Abstract][Full Text] [Related]
35. SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1
Agaimy A; Fuchs F; Moskalev EA; Sirbu H; Hartmann A; Haller F
Virchows Arch; 2017 Nov; 471(5):599-609. PubMed ID: 28555282
[TBL] [Abstract][Full Text] [Related]
36. SMARCA4-Deficient Thoracic Sarcoma: A Case Report and Review of Literature.
Stewart BD; Kaye F; Machuca T; Mehta HJ; Mohammed TL; Newsom KJ; Starostik P
Int J Surg Pathol; 2020 Feb; 28(1):102-108. PubMed ID: 31382829
[TBL] [Abstract][Full Text] [Related]
37. Partial Inactivation of the Chromatin Remodelers SMARCA2 and SMARCA4 in Virus-Infected Cells by Caspase-Mediated Cleavage.
Dudek AH; Pfaff F; Bolte H; Waguia Kontchou C; Schwemmle M
J Virol; 2018 Aug; 92(16):. PubMed ID: 29848589
[TBL] [Abstract][Full Text] [Related]
38. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
[TBL] [Abstract][Full Text] [Related]
39. SMARCA4/SMARCA2-deficient Carcinoma of the Esophagus and Gastroesophageal Junction.
Horton RK; Ahadi M; Gill AJ; Said S; Chen ZE; Bakhshwin A; Nichols M; Goldblum JR; Graham RP
Am J Surg Pathol; 2021 Mar; 45(3):414-420. PubMed ID: 33027072
[TBL] [Abstract][Full Text] [Related]
40. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.
Hoffman GR; Rahal R; Buxton F; Xiang K; McAllister G; Frias E; Bagdasarian L; Huber J; Lindeman A; Chen D; Romero R; Ramadan N; Phadke T; Haas K; Jaskelioff M; Wilson BG; Meyer MJ; Saenz-Vash V; Zhai H; Myer VE; Porter JA; Keen N; McLaughlin ME; Mickanin C; Roberts CW; Stegmeier F; Jagani Z
Proc Natl Acad Sci U S A; 2014 Feb; 111(8):3128-33. PubMed ID: 24520176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
